Novel therapeutic approaches to autoimmune demyelinating disorders.

abstract：:The use of the carbohydrate glucose as an energetic source is essential for an adequate function of the human body. The complex regulation of this molecule involves the coordinated action of various organs such as pancreas, liver and brain. Any disruption of this physiological balance may result in a dangerous comprom...

journal_title：Current pharmaceutical design

authors： González-Reyes RE,Aliev G,Ávila-Rodrigues M,Barreto GE

更新日期：2016-01-01 00:00:00

abstract：BACKGROUND:Diabetic dyslipidemia has specifics that differ from dyslipidemia in patients without diabetes, which contributes to accelerated atherosclerosis equally as dysglycemia. The aim of this study was to deduce the interdependence of diabetic dyslipidemia and cardiovascular diseases (CVD), therapeutic strategies a...

journal_title：Current pharmaceutical design

authors： Vavlukis M,Kedev S

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Bacterial cellulose (BC) has recently attained greater interest in various research fields, including drug delivery for biomedical applications. BC has been studied in the field of drug delivery, such as tablet coating, controlled release systems and prodrug design. OBJECTIVE:In the current work, we tested ...

journal_title：Current pharmaceutical design

authors： Ullah H,Badshah M,Correia A,Wahid F,Santos HA,Khan T

更新日期：2019-01-01 00:00:00

abstract：:Deubiquitinating enzymes (DUBs) remove ubiquitin and ubiquitin-like modifications from proteins and they have been known to contribute to processes relevant in microbial infection, such as immune responses pathways. Numerous viral and bacterial DUBs have been identified, and activities of several host DUBs are known t...

journal_title：Current pharmaceutical design

authors： Nanduri B,Suvarnapunya AE,Venkatesan M,Edelmann MJ

更新日期：2013-01-01 00:00:00

abstract：:Nonalcoholic fatty liver disease (NAFLD) affects about 20%-30% of the general population, and its clinical relevance arises from the fact that 20%-30% of these subjects develop non-alcoholic steatohepatitis (NASH), a condition at risk of cirrhosis progression. In addition NAFLD, and in particular NASH patients, are al...

journal_title：Current pharmaceutical design

authors： Petta S,Handberg A,Craxì A

更新日期：2013-01-01 00:00:00

abstract：:The development of radioligands to image beta-amyloid (A beta) plaques and neurofibrillary tangles (NFTs) in vivo in the aging human brain is an important and active area of radiopharmaceutical design. When used in combination with positron emission tomography (Pet) or single photon emission computed tomography (spect...

journal_title：Current pharmaceutical design

authors： Mathis CA,Wang Y,Klunk WE

更新日期：2004-01-01 00:00:00

abstract：:Over the last three decades, neoplasms have become the largest cause of human mortality due to both high tumor incidence and mortality. Chemotherapy is one of the main therapies employed to treat neoplasms. Although classical genotoxic drugs, such as cyclophosphamide, 5-FU, cisplatin and doxorubicin have been applied ...

journal_title：Current pharmaceutical design

authors： Quan C,Xiao J,Liu L,Duan Q,Yuan P,Zhu F

更新日期：2017-11-16 00:00:00

abstract：:Invasive fungal infections are a major cause of morbidity and mortality in immunosuppressed patients with fatality rates ranging from 30 % to 80 % in neutropenic patients. This results at least partly in difficulties obtaining a reliable and early diagnosis, followed by the fact that clinical symptoms are unspecific a...

journal_title：Current pharmaceutical design

authors： Lackner M,Lass-Flörl C

更新日期：2013-01-01 00:00:00

abstract：:The nanodelivery of therapeutics into the brain will require a step-change in thinking; overcoming the blood brain barrier is one of the major challenges to any neural therapy. The promise of nanotechnology is that the selective delivery of therapeutics can be delivered through to the brain without causing secondary d...

journal_title：Current pharmaceutical design

authors： Ellis-Behnke RG,Teather LA,Schneider GE,So KF

更新日期：2007-01-01 00:00:00

abstract：:Evasion of apoptosis, the cell's intrinsic death program, is a hallmark of human cancers including neuroblastoma. Also, failure to undergo apoptosis may cause treatment resistance, since the cytotoxic activity of anticancer therapies commonly used in the clinic, e.g. chemotherapy, gamma-irradiation or immunotherapy, i...

journal_title：Current pharmaceutical design

authors： Fulda S

更新日期：2009-01-01 00:00:00

abstract：:The final aim/target of Pharmaceutical Sciences is to design successful dosage forms for effective therapy, considering individual patient needs and compliance. Development of new drug entities, particularly using peptides and proteins, is growing in importance and attracting increased interest, as they are specifical...

journal_title：Current pharmaceutical design

authors： Degim IT,Celebi N

更新日期：2007-01-01 00:00:00

abstract：:The targeting of drugs to skeletal muscle is an emerging area of research. Driven by the need for new therapies to treat a range of muscle-associated diseases, these strategies aim to provide improved drug exposure at the site of action in skeletal muscle with reduced concentration in other tissues where unwanted side...

journal_title：Current pharmaceutical design

authors： Ebner DC,Bialek P,El-Kattan AF,Ambler CM,Tu M

更新日期：2015-01-01 00:00:00

abstract：:This review is based on carriers of natural origin such as polysaccharides, proteins, and cell derived entities which have been used for delivery of siRNA. To realize the therapeutic potential of a delivery system, the role of the carrier is of utmost importance. Historical aspects of viral vectors, the first carriers...

journal_title：Current pharmaceutical design

authors： Karunaratne DN,Jafari M,Ranatunga RJ,Siriwardhana A

更新日期：2015-01-01 00:00:00

abstract：:Osteoblasts pass through a sequence of events controlled by hormones and transcriptional factors ensuring proper development of phenotype and functional properties until the osteoblast enter the osteocyte phenotype and/or undergo apoptosis. During its life cycle, the osteoblasts proliferate, deposit matrix proteins an...

journal_title：Current pharmaceutical design

authors： Gordeladze JO,Reseland JE,Drevon CA

更新日期：2001-03-01 00:00:00

abstract：:Stroke is a leading cause of death and disability worldwide. Conventional treatment has a limitation of very narrow therapeutic time window and its devastating nature necessitate a novel regenerative approach. Transplanted stem cells resulted in functional recovery through multiple mechanisms including neuroprotection...

journal_title：Current pharmaceutical design

authors： Kwak KA,Kwon HB,Lee JW,Park YS

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Oxidative stress and inflammation are key parameters in developing metabolic disorders. Hence, antioxidant intake might be an appropriate approach. Several studies have evaluated the effect of coenzyme Q10 (CoQ10) supplementation on lipid profile among patients with metabolic diseases, though f...

journal_title：Current pharmaceutical design

authors： Sharifi N,Tabrizi R,Moosazadeh M,Mirhosseini N,Lankarani KB,Akbari M,Chamani M,Kolahdooz F,Asemi Z

更新日期：2018-01-01 00:00:00

abstract：:Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine released from T-cells and macrophages, and is a key molecule in inflammation. Although a detailed understanding of the biological functions of MIF has not yet been found, it is known that MIF catalyzes the tautomerization of phenylpyruvate and...

journal_title：Current pharmaceutical design

authors： Orita M,Yamamoto S,Katayama N,Fujita S

更新日期：2002-01-01 00:00:00

abstract：:DNA methylation, a major regulator of epigenetic modifications has been shown to alter the expression of genes that are involved in aspects of glucose metabolism such as glucose intolerance, insulin resistance, β-cell dysfunction and other conditions, and it ultimately leads to the pathogenesis of type 2 diabetes mell...

journal_title：Current pharmaceutical design

authors： Alam F,Islam MA,Gan SH,Mohamed M,Sasongko TH

更新日期：2016-01-01 00:00:00

abstract：:Adverse reactions after iodinate contrast media (ICM) administration have been observed, which can be classified as immediate (i.e., occurring within one hour after administration) and delayed or non-immediate (i.e., occurring more than one hour after administration). Even though the incidence of ICM adverse reactions...

journal_title：Current pharmaceutical design

authors： Guéant-Rodriguez RM,Romano A,Barbaud A,Brockow K,Guéant JL

更新日期：2006-01-01 00:00:00

abstract：:The prevalence of type 2 diabetes is rising at an alarming rate worldwide. Coronary artery disease (CAD) is the leading cause of morbidity and mortality in the diabetic population. Future CAD risk should be routinely assessed in patients with diabetes as specific subgroups might benefit from information derived from c...

journal_title：Current pharmaceutical design

authors： Karastergiou K,Kaski JC

更新日期：2008-01-01 00:00:00

abstract：:There is growing evidence for the involvement of glutamatergic abnormalities in schizophrenia. Uncompetitive NMDA receptor (NMDAR) antagonists induce effects closely resembling both the positive and negative symptoms of schizophrenia; candidate risk genes for schizophrenia converge on the NMDAR expressing synapse; and...

journal_title：Current pharmaceutical design

authors： Stone JM

更新日期：2009-01-01 00:00:00

abstract：:Mesenchymal stem cells (MSCs) were first isolated more than 50 years ago from the bone marrow. Currently MSCs may also be isolated from several alternative sources and they have been used in more than a hundred clinical trials worldwide to treat a wide variety of diseases. The MSCs mechanism of action is undefined and...

journal_title：Current pharmaceutical design

authors： de Girolamo L,Lucarelli E,Alessandri G,Avanzini MA,Bernardo ME,Biagi E,Brini AT,D'Amico G,Fagioli F,Ferrero I,Locatelli F,Maccario R,Marazzi M,Parolini O,Pessina A,Torre ML,Italian Mesenchymal Stem Cell Group

更新日期：2013-01-01 00:00:00

abstract：:Many of the most debilitating symptoms for psychiatric disorders such as schizophrenia remain poorly treated. As such, the development of novel treatments is urgently needed. Unfortunately, the costs associated with high failure rates for investigational compounds as they enter clinical trials has led to pharmaceutica...

journal_title：Current pharmaceutical design

authors： Wylie KP,Smucny J,Legget KT,Tregellas JR

更新日期：2016-01-01 00:00:00

abstract：:Chronic pain is a widespread healthcare problem affecting not only the patient but in many ways all the society. Chronic pain is a disease itself that endures for a long period of time and it is resistant to the majority of medical treatments that provide modest improvements in pain and minimum improvements in physica...

journal_title：Current pharmaceutical design

authors： Del Bufalo A,Cesario A,Salinaro G,Fini M,Russo P

更新日期：2014-01-01 00:00:00

abstract：:Marine invertebrates, especially tunicates, are a lucrative resource for the discovery of new lead compounds for the development of clinically utilized drugs. This review describes the isolation, synthesis and biological activities of several classes of marine-derived butenolide natural products, namely rubrolides and...

journal_title：Current pharmaceutical design

authors： Bracegirdle J,Keyzers RA

更新日期：2020-01-01 00:00:00

abstract：:Recent advances in the fabrication, characterization and application of micro- and nano-particles that possess a non-uniform internal structure are reviewed. The particle structures include core-shell particles, particles with multiple cores or a multi-layered structure, porous particles with both regular and random p...

journal_title：Current pharmaceutical design

authors： Čejková J,Štêpánek F

更新日期：2013-01-01 00:00:00

abstract：:Nanogels are nanosized hydrogel particles formed by physical or chemical cross-linked polymer networks. The advantageous properties of nanogels related to the ability of retaining considerable amount of water, the biocompatibility of the polymers used, the ability to encapsulate and protect a large quantity of payload...

journal_title：Current pharmaceutical design

authors： Maya S,Sarmento B,Nair A,Rejinold NS,Nair SV,Jayakumar R

更新日期：2013-01-01 00:00:00

abstract：:Recent decades mark a great progress in the treatment of HIV infection. What was once a deadly disease is now a chronic infection. However, HIV-infected patients are prone to develop comorbidities, which severely affect their daily functions. For example, a large population of patients develop a variety of neurologica...

journal_title：Current pharmaceutical design

authors： Bertrand L,Nair M,Toborek M

更新日期：2016-01-01 00:00:00

abstract：:DNA-topoisomerases, a family of DNA-processing enzymes, represent the pharmacological target of major clinically useful chemotherapeutic agents. These drugs essentially act by trapping a topoisomerase-DNA cleavable complex, an intermediate in the enzyme s catalytic cycle. Research activity in this field continues to g...

journal_title：Current pharmaceutical design

authors： Gatto B,Capranico G,Palumbo M

更新日期：1999-03-01 00:00:00

abstract：:Mechanical loading provides an anabolic stimulus for bone. More importantly, the mechanosensing apparatus in bone directs osteogenesis to where it is most needed for improving bone strength. The biological processes involved in bone mechanotransduction are poorly understood and further investigation of the molecular m...

journal_title：Current pharmaceutical design

authors： Turner CH,Robling AG

更新日期：2004-01-01 00:00:00